Literature DB >> 2376278

Termination of early pregnancy through a combination of the antiprogestin and prostaglandin analogue.

B Maria1, F Stampf, A Goepp, C Dubois.   

Abstract

Termination of early pregnancy (less than 49 days of amenorrhea) was induced in 75 patients with the combination of the antigestagen mifepristone and a prostaglandin analogue, meteneprost. After 48 h a single oral dose of 600 mg of mifepristone was followed by a 10 mg meteneprost vaginal pessary. Pregnancy was confirmed by clinical and ultrasound examinations and plasma HCG assessment. Complete abortion occurred in 72 patients (96%) and the three others required a surgical uterine aspiration. Bleeding continued for 4 to 12 days (mean = 8). Uterine pain and side effects occurred during the 3 h following the use of prostaglandin. Only minor analgesic were required in 30 patients. The combination of mifepristone and meteneprost is a safe and effective method to terminate an early pregnancy.

Entities:  

Keywords:  Abortion, Induced; Biology; Bleeding; Contraception; Contraceptive Usage; Developed Countries; Diseases; Endocrine System; Europe; Examinations And Diagnoses; Family Planning; Fertility Control, Postconception; France; Gonadotropins; Gonadotropins, Chorionic--analysis; Hemic System; Hemoglobin Level--analysis; Hormones; Incidence; Laboratory Examinations And Diagnoses; Measurement; Mediterranean Countries; Method Acceptability; Physiology; Pregnancy; Pregnancy, First Trimester; Prostaglandins--administraction and dosage; Prostaglandins--side effects; Reproduction; Research Methodology; Signs And Symptoms; Western Europe

Mesh:

Substances:

Year:  1990        PMID: 2376278     DOI: 10.1016/0028-2243(90)90092-f

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials.

Authors:  Blanchard Clara; Vanderkam Paul; Pouchain Denis; Mignot Stéphanie; Vaillant-Roussel Hélène; Boussageon Rémy
Journal:  Eur J Clin Pharmacol       Date:  2019-08-21       Impact factor: 2.953

Review 2.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.